Table 1 Baseline characteristics of the 49 pretreated viral isolates
Characteristic Value | |
|---|---|
Age, median years (IQR) | 44 (23-80) |
Plasma HIV-1 RNA level, median copies/ml (IQR) | 4900 (range 306-10.000.000) |
Previous antiretroviral therapy, median months (IQR) | 124 (range 1-193) |
Treatment interruption (TI) at time of sample-taking | |
Yes | 13 (26,5) |
No | 36 (73,5) |
Duration of TI, median months (IQR) | 4 (1-6) |
NRTI used in antiretroviral treatment at time of sample taking | |
Yes | 27 (55,1) |
No | 22 (44,9) |
Prior mono nucleoside treatment | |
Yes | 20 (40,8) |
No | 29 (59,2) |
Prior dual nucleoside treatment | |
Yes | 28 (57,1) |
No | 21 (42,9) |
3TC used in antiretroviral treatment at time of sample-taking | |
Yes | 18 (36,7) |
No | 31 (63,3) |
FTC used in antiretroviral treatment at time of sample-taking | |
Yes | 3 (6,1) |
No | 46 (93,9) |
NNRTI used in antiretroviral treatment at time of sample taking | |
Yes | 3 (6,1) |
No | 46 (93,9) |
Prior NNRTI-treatment | |
Yes | 36 (73,5) |
No | 13 (26,5) |
PI used in antiretroviral treatment at time of sample taking | |
Yes | 21 (42,9) |
No | 28 (57,1) |
Prior PI-treatment | |
Yes | 45 (91,8) |
No | 4 (8,2) |
Sequences containing TAMs | 24 (49) |
TAMs, median no. (IQR) | 3 (1-4) |
M184V mutation present | |
Yes | 16 (32,7) |
No | 33 (67,3) |
Sequences containing NNRTI resistance delivering mutations | 11 (22,4) |
NNRIT resistance delivering mutations, median no. (IQR) | 1 (1-3) |